The SLE and LN market offers opportunities with the launch of 10 late-stage pipeline drugs improving safety and efficacy, contrasting with the current generic treatments. However, growth is challenged ...
Long-term use of glucocorticoids (GCs) for the treatment of lupus is very common, however, it has also been associated with side effects like high blood pressure, diabetes, infection, and osteoporosis ...
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The SLE clinical trial analysis report delivers ...
Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...
Please provide your email address to receive an email when new articles are posted on . Patients with systemic lupus with a history of skin rashes are likely to have high interferon levels. This ...
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...
Add Yahoo as a preferred source to see more of our stories on Google. Three patients in the UK have received a 'groundbreaking' treatment for lupus, including Katie Tinkler, who received the treatment ...
It is my view that B-cell therapy will likely become an important part of the treatment paradigm in SLE over the next 3–5 years. I think the data are suitably strong to justify the approval of ...
A Phase II study was subsequently performed by the LBSL02/99 group, which enrolled 449 patients who met American College of Rheumatology (ACR) diagnostic criteria for SLE, had active SLE disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results